3-(6-methoxynaphthalen-2-yl)-butyramide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(6-methoxynaphthalen-2-yl)-butyramide
• 英文别名: 3-(6-methoxy-[2]naphthyl)-butyric acid amide；3-(6-Methoxy-[2]naphthyl)-buttersaeure-amid；3-(6-Methoxynaphthalen-2-yl)butanamide
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: VLLQPJAQYXDAKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴-6-甲氧基萘 在 sodium hydroxide 、 乙醚 、 magnesium 、 苯 作用下， 生成 3-(6-methoxynaphthalen-2-yl)-butyramide
  参考文献：
  名称：

  The Reaction of Methylmagnesium Iodide with β-(1-Hydroxy-3,4-dihydro-2-naphthyl)-butyric Acid Lactone¹

  摘要：

  DOI：

  10.1021/ja01155a504

文献信息

• Compounds advantageous in the treatment of central nervous system diseases and disorders
  申请人：Pesyan Amir

  公开号：US09206143B2

  公开（公告）日：2015-12-08

  A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.

  描述了一系列显示抗惊厥活性的新化合物。这类药用活性化合物可能在治疗其他中枢神经系统（“CNS”）疾病和障碍方面发挥作用，如焦虑、抑郁、失眠、偏头痛、精神分裂症、帕金森病、痉挛、阿尔茨海默病和躁郁症。此外，这些化合物还可能作为镇痛剂（例如用于慢性或神经性疼痛的治疗）和作为神经保护剂在中风、慢性神经退行性疾病（如阿尔茨海默病和亨廷顿病）以及创伤性脑部和/或脊髓损伤的治疗中发挥作用。此外，这些/此类化合物还可能在癫痫持续状态的治疗和/或作为化学对抗措施方面发挥作用。
• NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
  申请人：Pesyan Amir

  公开号：US20110046128A1

  公开（公告）日：2011-02-24

  A series of novel compounds showing anticonvulsant, chemical countermeasure(s), and analgesic activities is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.

  本文介绍了一系列新型化合物，具有抗惊厥、化学对抗剂和镇痛活性。这些药物活性化合物也可能在治疗其他中枢神经系统（“CNS”）疾病和障碍方面发挥作用，如焦虑、抑郁、失眠、偏头痛、精神分裂症、帕金森病、痉挛、阿尔茨海默病和双相情感障碍。此外，这些化合物还可以作为镇痛剂（例如，用于慢性或神经性疼痛的治疗）和作为神经保护剂，有助于治疗中风、慢性神经退行性疾病（如阿尔茨海默病和亨廷顿病）以及创伤性脑和/或脊髓损伤。此外，这些化合物还可以用于治疗癫痫持续状态和/或作为化学对抗剂。
• US9206143B2
  申请人：——

  公开号：US9206143B2

  公开（公告）日：2015-12-08
• US9212155B2
  申请人：——

  公开号：US9212155B2

  公开（公告）日：2015-12-15
• [EN] NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS SERVANT À TRAITER LES MALADIES ET TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：AURIMMED PHARMA INC

  公开号：WO2009117515A2

  公开（公告）日：2009-09-24

  A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system ("CNS") diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.